X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (439) 439
index medicus (428) 428
melanoma (319) 319
proto-oncogene proteins b-raf - genetics (283) 283
mutation (256) 256
proto-oncogene proteins b-raf - antagonists & inhibitors (218) 218
cancer (205) 205
oncology (203) 203
melanoma - drug therapy (194) 194
cell line, tumor (186) 186
braf (172) 172
melanoma - genetics (166) 166
animals (157) 157
vemurafenib (145) 145
proto-oncogene proteins b-raf - metabolism (144) 144
indoles - pharmacology (142) 142
sulfonamides - pharmacology (142) 142
kinases (133) 133
melanoma - pathology (130) 130
protein kinase inhibitors - pharmacology (124) 124
b-raf (119) 119
metastatic melanoma (119) 119
neoplasms (112) 112
research (111) 111
mice (108) 108
cell biology (106) 106
article (105) 105
antineoplastic agents - pharmacology (102) 102
tumors (101) 101
acquired-resistance (100) 100
mutations (100) 100
genetic aspects (99) 99
female (96) 96
resistance (88) 88
gene mutations (86) 86
health aspects (84) 84
male (84) 84
metastasis (84) 84
signal transduction (84) 84
antineoplastic agents - therapeutic use (83) 83
biochemistry & molecular biology (82) 82
care and treatment (82) 82
activation (78) 78
proteins (77) 77
multidisciplinary sciences (74) 74
protein kinase inhibitors - therapeutic use (74) 74
apoptosis (73) 73
indoles - therapeutic use (73) 73
melanoma - metabolism (73) 73
sulfonamides - therapeutic use (73) 73
plx4032 (72) 72
drug resistance (70) 70
pathway (70) 70
skin neoplasms - drug therapy (63) 63
drug therapy (62) 62
phosphorylation (62) 62
cell proliferation - drug effects (61) 61
map kinase signaling system - drug effects (61) 61
raf (61) 61
survival (59) 59
signal transduction - drug effects (58) 58
skin neoplasms - genetics (57) 57
drug resistance, neoplasm - drug effects (56) 56
medicine (56) 56
drug resistance, neoplasm (55) 55
inhibition (55) 55
xenograft model antitumor assays (55) 55
inhibitors (54) 54
kinase (54) 54
middle aged (54) 54
research article (53) 53
melanoma - enzymology (51) 51
skin cancer (51) 51
digestive system diseases (50) 50
drug resistance, neoplasm - genetics (50) 50
endocrine system diseases (48) 48
improved survival (48) 48
malignant-melanoma (48) 48
apoptosis - drug effects (47) 47
extracellular signal-regulated kinase (47) 47
skin neoplasms - pathology (47) 47
map kinase (46) 46
pharmacology & pharmacy (46) 46
cancer therapies (45) 45
cells (45) 45
mek (45) 45
raf protein (45) 45
adult (44) 44
gene expression (44) 44
science (44) 44
patients (43) 43
therapy (43) 43
cell proliferation (42) 42
open-label (42) 42
chemotherapy (41) 41
development and progression (41) 41
aged (39) 39
expression (39) 39
metastases (39) 39
neoplasms - drug therapy (39) 39
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncogene, ISSN 0950-9232, 05/2007, Volume 26, Issue 22, pp. 3291 - 3310
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2009, Volume 4, Issue 11, pp. e7887 - e7887
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2009, Volume 106, Issue 48, pp. 20411 - 20416
Journal Article
Future Oncology, ISSN 1479-6694, 2009, Volume 5, Issue 6, pp. 775 - 778
Evaluation of: Niculescu-Duvaz D, Gaulon C, Dijkstra HP et al.: Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue... 
MEK | Inhibitors | PLX4032 | Sorafenib | Melanoma | BRAF | RAF265 | R7204 | PLX4720 | inhibitors | CELLS | sorafenib | CYCLIN D1 | KINASE | melanoma | MALIGNANT-MELANOMA | CHRONIC MYELOID-LEUKEMIA | ONCOLOGY | PATHWAY | GROWTH | KIT | B-RAF | ERK
Journal Article
Journal Article
Expert Opinion on Emerging Drugs, ISSN 1472-8214, 12/2009, Volume 14, Issue 4, pp. 633 - 648
Journal Article
Annals of Oncology, ISSN 0923-7534, 2009, Volume 20, Issue 4, pp. v35 - v40
Journal Article
Nature, ISSN 0028-0836, 03/2010, Volume 464, Issue 7287, pp. 427 - 430
Tumours with mutant BRAF are dependent on the RAF–MEK–ERK signalling pathway for their growth. We found that ATP-competitive RAF inhibitors inhibit ERK... 
SELECTIVE INHIBITOR | ACTIVATION | MELANOMA | MECHANISM | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | HETERODIMERIZATION | KINASE INHIBITOR | B-RAF | CRAF | ONCOGENIC BRAF | Neoplasms - metabolism | ras Proteins - genetics | Phosphorylation | raf Kinases - antagonists & inhibitors | Humans | Protein Multimerization | Transcriptional Activation - drug effects | ras Proteins - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | Mitogen-Activated Protein Kinase Kinases - metabolism | Neoplasms - genetics | Adenosine Triphosphate - metabolism | Indoles - pharmacology | raf Kinases - genetics | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Cell Line | raf Kinases - chemistry | Catalytic Domain | Neoplasms - enzymology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | MAP Kinase Signaling System - drug effects | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Protein Binding | Mice | Protein Kinase Inhibitors - pharmacology | Protein Kinase Inhibitors - metabolism | Care and treatment | Enzyme inhibitors | Gene mutations | Cellular signal transduction | Genetic aspects | Research | Health aspects | Cancer | Proteins | Competition | Drugs | Mutation | Kinases | Tumors | Index Medicus
Journal Article